Activation of native TRPC1/C5/C6 channels by endothelin-1 is mediated by both PIP₃ and PIP₂ in rabbit coronary artery myocytes

Sohag N. Saleh, Anthony P. Albert and William A. Large

Ion Channels and Cell Signalling Research Centre, Division of Basic Medical Sciences, St George's, University of London, Cranmer Terrace, London SW17 ORE, UK

We investigate activation mechanisms of native TRPC1/C5/C6 channels (termed TRPC1 channels) by stimulation of endothelin-1 (ET-1) receptor subtypes in freshly dispersed rabbit coronary artery myocytes using single channel recording and immunoprecipitation techniques. ET-1 evoked non-selective cation channel currents with a unitary conductance of 2.6 pS which were not inhibited by either ET_A or ET_B receptor antagonists, respectively BQ-123 and BQ788, when administered separately. However, in the presence of both antagonists, ET-1-evoked channel activity was abolished indicating that both ET_A and ET_B receptor stimulation activate this conductance. Stimulation of both ET_A and ET_B receptors evoked channel activity which was inhibited by the protein kinase C (PKC) inhibitor chelerythrine and by anti-TRPC1 antibodies indicating that activation of both receptor subtypes causes TRPC1 channel activation by a PKC-dependent mechanism. ET_A receptor-mediated TRPC1 channel activity was selectively inhibited by phosphoinositol-3-kinase (PI-3-kinase) inhibitors wortmannin (50 nm) and PI-828 and by antibodies raised against phosphoinositol-3,4,5-trisphosphate (PIP₃), the product of PI-3-kinase-mediated phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP₂). Moreover, exogenous application of diC8-PIP₃ stimulated PKC-dependent TRPC1 channel activity. These results indicate that stimulation of ETA receptors evokes PKC-dependent TRPC1 channel activity through activation of PI-3-kinase and generation of PIP₃. In contrast, ET_{B} receptor-mediated TRPC1 channel activity was inhibited by the PI-phospholipase C (PI-PLC) inhibitor U73122. 1-Oleoyl-2-acetyl-sn-glycerol (OAG), an analogue of diacylglycerol (DAG), which is a product of PI-PLC, also activated PKC-dependent TRPC1 channel activity. OAG-induced TRPC1 channel activity was inhibited by anti-phosphoinositol-4,5-bisphosphate (PIP₂) antibodies and high concentrations of wortmannin (20 μ M) which depleted tissue PIP₂ levels. In addition exogenous application of diC8-PIP₂ activated PKC-dependent TRPC1 channel activity. These data indicate that stimulation of ET_{B} receptors evokes PKC-dependent TRPC1 activity through PI-PLC-mediated generation of DAG and requires a permissive role of PIP₂. In conclusion, we provide the first evidence that stimulation of ET_A and ET_B receptors activate native PKC-dependent TRPC1 channels through two distinct phospholipids pathways involving a novel action of PIP₃, in addition to PIP₂, in rabbit coronary artery mvocvtes.

(Received 14 August 2009; accepted after revision 16 September 2009; first published online 21 September 2009) **Corresponding author** A. Albert: Ion Channels and Cell Signalling Research Centre, Division of Basic Medical Sciences, St George's, University of London, Cranmer Terrace, London SW17 0RE, UK. Email: aalbert@sgul.ac.uk

Abbreviations AgP, antigenic peptide; CPA, cyclopiazonic acid; DAG, diacylglycerol; ET-1, endothelin-1; OAG, 1-oleoyl-2-acetyl-*sn*-glycerol; PI-3-kinase, phosphoinositol-3-kinase; PIP₂, phosphatidylinositol-4,5-bisphosphate; phosphatidylinositol-3,4,5-trisphosphate; PLC, phosphoslipase C; PKC, protein kinase C; TRPC, canonical transient receptor potential.

Introduction

Endothelin-1 (ET-1) produces vasoconstriction by a direct action on vascular smooth muscle cells through stimulation of predominantly ET_A receptors, although ET_B receptors are involved in some vascular beds (Sumner *et al.* 1992; Davenport & Battistini, 2002). Moreover in the coronary circulation activation of ET-1 receptors has been linked to exaggerated constriction of human coronary artery leading to myocardial ischaemia in coronary artery disease (Schiffrin & Touyz, 1998; Kinlay *et al.* 2001).

ET-1-induced vasoconstriction is mediated almost entirely by influx of Ca²⁺ ions through voltage-independent ion channels (see Miwa et al. 2005). These data suggest that ET-1 contracts vascular smooth muscle by opening Ca²⁺-permeable non-selective cation channels. Consistent with this notion we demonstrated that ET-1 activates two distinct types of canonical transient receptor potential (TRPC) channels in freshly dispersed rabbit coronary myocytes. At low concentrations (1-10 nm) ET-1 activates a non-selective cation channel with four subconductance states of between 16 and 68 pS (Peppiatt-Wildman et al. 2007). These responses were mediated mainly by ET_A receptors and were mimicked by the diacylglycerol (DAG) analogue, 1-oleoyl-2-acetyl-sn-glycerol (OAG) via a protein kinase C (PKC)-independent mechanism. Evidence indicated that this cation channel protein is a heteromeric structure consisting of TRPC3/TRPC7 subunits (Peppiatt-Wildman et al. 2007).

In contrast at higher concentrations (100 nM) ET-1 evokes a PKC-dependent 2.6 pS Ca²⁺-permeable cation channel which has characteristics of a heteromeric TRPC1/TRPC5/TRPC6 structure (subsequently referred to as TRPC1 channels, Saleh *et al.* 2008). With this concentration of ET-1 the TRPC3/TRPC7 conductance is not observed.

In the present study we have investigated the transduction mechanisms linking ET-1 receptors to native TRPC1 ion channels described above in coronary artery myocytes. The results demonstrate that TRPC1 channels may be activated by stimulation of either ET_{A} or ET_{B} receptors using two distinct phosphoinositide signalling pathways involving respectively phosphatidylinositol 3,4,5-trisphosphate (PIP₃) and phosphatidylinositol 4,5-bisphosphate (PIP₂). This is the first demonstration that PIP₃, in addition to PIP₂, activates native TRPC1 channels.

Methods

Cell isolation

New Zealand White rabbits (2-3 kg) were killed using I.V. sodium pentobarbitone (120 mg kg^{-1}) , in accordance

with the UK Animals (Scientific Procedures Act) 1986). Experimental methods were carried out as specified by St George's animal welfare committee and according to the policies of *The Journal of Physiology* (Drummond, 2009). Right and left anterior descending coronary arteries were dissected free from fat and connective tissue in physiological salt solution containing (mM): NaCl (126), KCl (6), glucose (10), Hepes (11), MgCl₂ (1.2) and CaCl₂ (1.5), with pH adjusted to 7.2 with 10 M NaOH. An incision was made along the longitudinal axis of the blood vessels and the exposed endothelium was gently removed using a cotton bud. Enzymatic digestion and smooth muscle cell isolation were subsequently carried using methods previously described (Saleh *et al.* 2006).

Electrophysiology

Single channel currents were recorded in voltage-clamp mode using cell-attached and inside-out patch configurations (Hamill et al. 1981) with a HEKA EPC 8 patch-clamp amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany) at room temperature (20-23°C). Patch pipettes were manufactured from borosilicate glass to produce pipettes with resistances of $6-10 M\Omega$ for isolated patch recording when filled with patch pipette solution. To reduce 'line' noise the recording chamber (vol. ca 150–200 μ l) was perfused using two 20 ml syringes, one filled with external solution and the other used to drain the chamber, in a 'push and pull' technique. The external solution could be exchanged twice within 30 s. In cell-attached patch recording, the membrane potential was set to $\sim 0 \,\mathrm{mV}$ using a high KCl bathing solution (see below). In both cell-attached and inside-out patch recordings, +70 mV was applied to the patch and held at this level except for measuring current-voltage (I-V) relationships when the applied patch voltage was manually altered between +120 mV and -50 mV. According to convention in the text membrane potential is given with respect to the internal potential and thus, the resting holding potential is referred to as -70 mV.

Single channel currents were initially recorded onto digital audiotape (DAT) using a Sony PCM-R300 digital tape-recorder (BioLogic Science Instruments, Claix, France) at a bandwidth of 5 kHz (HEKA EPC 8 patch-clamp amplifier) and a sample rate of 48 kHz. For off-line analysis, single channel currents were filtered at 100 Hz (see below, -3 db, low pass 8-pole Bessel filter, model LP02, Frequency Devices Inc., Ottawa, IL, USA) and acquired using a Digidata 1322A and pCLAMP 9.0 at a sampling rate of 1 kHz. Data were captured with a Dell Dimension 5150 personal computer.

Single channel current amplitudes were calculated from idealised traces of at least 60 s in duration using the 50% threshold method and analysed using pCLAMP

v.9.0 software with events lasting for <6.664 ms (2 × rise time for a 100 Hz, -3 db, low pass filter) being excluded from analysis. Single channel current amplitude histograms were plotted and fitted with Gaussian curves with the peak of these curves determining the unitary amplitude of the single channel currents. Open probability (*NP*_o) was calculated automatically using pCLAMP 9. Figure preparation was carried out using Origin 6.0 software (OriginLab Corp., Northampton, MA, USA) where inward single channel openings are shown as downward deflections.

Solutions and drugs

In cell-attached patch experiments the membrane potential was set to approximately 0 mV by perfusing cells in a KCl external solution containing (mM): KCl (126), CaCl₂ (1.5), Hepes (10) and glucose (11), pH adjusted to 7.2 with 10 M KOH. Nicardipine (5 μ M) was also included to prevent smooth muscle cell contraction by blocking Ca²⁺ entry through voltage-dependent Ca²⁺ channels. The bathing solution used in inside-out experiments (intracellular solution) contained (mM): CsCl (18), caesium aspartate (108), MgCl₂ (1.2), Hepes (10), glucose (11), BAPTA (1), CaCl₂ (0.48, free internal Ca²⁺ concentration approximately 100 nM as calculated using EQCAL software), Na₂ATP (1) and NaGTP (0.2), pH 7.2 with Tris.

The patch pipette solution used for both cell-attached and inside-out patch recording (extracellular solution) was K⁺ free and contained (mM): NaCl (126), CaCl₂ (1.5), Hepes (10), glucose (11), TEA (10), 4-AP (5), iberiotoxin (0.0002), 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS) (0.1), niflumic acid (0.1) and nicardipine (0.005), pH adjusted to 7.2 with NaOH. Under these conditions voltage-dependent Ca²⁺ currents, K⁺ currents, swell-activated Cl⁻ currents and Ca²⁺-activated Cl⁻ conductances are abolished and non-selective cation currents could be recorded in isolation.

Anti-TRPC1 (which detects TRPC1 proteins with a predicted molecular mass of ~100 kDa) and anti-PIP₂ antibodies (which detect liposome complex of PIP₂ molecules with a predicted molecular mass of ~75 kDa, see manufacturer's data sheet and Fukami *et al.* 1988) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and alomone labs (Israel), anti-PIP₃ antibodies were from MBL (Japan) and anti- β -actin antibodies were from Sigma (UK). Pre-incubation of anti-TRPC1 antibodies with its antigenic peptide was carried out in a 1:2 ratio for at least 2 h in control experiments. Unless otherwise stated all other drugs were purchased from Calbiochem (UK), Sigma (UK) or Tocris (UK) and agents were dissolved in distilled H₂O or DMSO (0.1%). DMSO alone had no effect on channel activity. The values are

the mean of *n* cells \pm S.E.M. Statistical analysis was carried out using paired (comparing effects of agents on the same cell) or unpaired (comparing effects of agents between cells) Students' *t* test with the level of significance set at P < 0.05.

Immunoprecipitation and Western blotting

Dissected tissues were flash frozen and stored in 10 mM TRIS-HCl (pH 7.4) at -80° C for subsequent use. Tissues were defrosted and mechanically disrupted with an Ultraturrax homogeniser and further disrupted by sonication on ice for at least 2 h. Tissues were subsequently centrifuged at 25 000 g for 30 min at 4°C and the supernatant was discarded. The total cell lysate (TCL) was then collected by centrifugation at 11 200 g for 10 min in 10 mg ml⁻¹ RIPA lysis buffer (Santa Cruz Biotechnology), supplemented with protease inhibitors. Protein content was quantified using the Bio-Rad protein dye reagent (Bradford method). TCL was retained on ice for subsequent experimental procedures including dot-blots and immunoprecipitation. Dot-blots were carried out by 'spotting' 2–5 μ l of TCL on prepared immobilon-p polyvinvlidene difluoride (PVDF) membranes. Membranes were allowed to dry prior to detection using conventional Western blotting techniques (see later). The immunoprecipitation protocol was carried out using the Millipore Catch and Release^(K) kit, where spin columns were loaded with 500 μ g of TCL and 2–6 μ g of antibody and immunoprecipitated for 2 h at room temperature.

Immunoprecipitated samples were eluted with Laemmli sample buffer and incubated at 60°C for 5 min. One-dimensional protein gel electrophoresis was performed in 4-12% Bis-Tris Gels in a Novex mini-gel system (Invitrogen) with $10-20 \,\mu g$ of total protein loaded in each lane. Separated proteins were transferred onto PVDF membranes using the Invitrogen iBlot apparatus. Western blotting was subsequently carried out on membranes which were incubated with the appropriate primary antibody for 2 h at room temperature. Where possible, alternative antibodies raised against different epitopes were used for immunoprecipitation and Western blot analysis. Following antibody removal membranes were washed for 2 h with milk/phosphate-buffered saline with Tween 20 (PBST) and were subsequently incubated with horseradish peroxidase-conjugated secondary antibody diluted 1:1000-5000 in milk/PBST. Membranes were then washed 3 times for 15 min in PBST, followed by a final wash in PBS before being treated with ECL chemiluminescence reagents (Pierce Biotechnology, Inc., Rockford, IL, USA) for 1 min and exposed to photographic films. Data shown represents n values of at least three separate experiments.

Results

Stimulation of ET_A and ET_B receptors activate 2–3 pS cation channel currents in rabbit coronary artery myocytes

In initial experiments we investigated the identity of the ET-1 receptor subtype involved in activating native 2–3 pS cation channel currents. For these experiments 100 nM ET-1 was used since at these concentrations ET-1 does not activate the TRPC3/C7 conductance expressed in this preparation (see Peppiatt-Wildman *et al.* 2007 and Introduction) and the 2–3 pS conductance is recorded in isolation. Both ET_A and ET_B G-protein-coupled receptors are expressed in vascular smooth muscle (see

Miwa *et al.* 2005) and therefore we studied the effect of selective concentrations of ET_A and ET_B receptor antagonists, respectively BQ-123 and BQ-788 (Davenport, 2002), on ET-1-induced native 2–3 pS channel activity in cell-attached patches from freshly dispersed coronary artery myocytes.

Figure 1*A*, *E* and *F* shows that bath application of 100 nM ET-1 activated cation channel activity at -70 mV which had a mean peak open probability (*NP*_o) of 0.25 ± 0.07 (n = 10) and was composed of channel openings with a unitary conductance of 2.6 pS and a reversal potential (E_r) of about 0 mV. These responses were seen in approximately 90% of patches tested. Figure 1*Ab* illustrates that the channel current amplitude histogram of




Figure 1. Stimulation of ET_A and ET_B receptors activates 2–3 pS cation channel currents in cell-attached patches from freshly dispersed coronary artery myocytes

Aa, bath application of 100 nm ET-1 induced cation channel activity at an applied patch voltage of +70 mV. According to convention we will refer to this as -70 mV membrane potential throughout the text (see Methods). *Ab*, amplitude histogram of channel currents shown in *Aa* could be fitted with the sum of four Gaussian curves indicating 1 closed and 3 multiple open levels inferring that the patch contained at least 3 channels. *B* and *C*, ET-1 evoked cation channel activity in the presence of respectively either the ET_A receptor antagonist 100 nm BQ-123 or the ET_B receptor antagonist 100 nm BQ-788. *D* and *F*, ET-1-induced cation channel activity was blocked in the presence of a mixture of 100 nm BQ-123 and 100 nv BQ-788 at -70 mV. *E*, *I*–*V* relationship of cation channel currents evoked by ET-1 (open circles), ET-1 in the presence of BQ-123 (open squares) and ET-1 in the presence of BQ-788 (filled squares) showing that they all had a unitary conductance of 2.6 pS and *E*_r of about 0 mV. Each point represents at least *n* = 6. *F*, mean data showing neither BQ-123 nor BQ-788 inhibited ET-1-evoked cation channel activity when applied separately. However when the antagonists were added together ET-1-evoked cation channel activity was abolished. Each value is the mean of 10 patches.

ET-1-evoked channel activity shown in Fig. 1Aa could be fitted by the sum of four Gaussian curves representing one closed and three open levels of the same conductance, i.e. there were at least three channels in the patch. Figure 1*B* and *F* shows that pre-treatment with the ET_A receptor antagonist 100 nM BQ-123 for 5 min had no effect on ET-1-induced channel activity (n = 10). In addition, Fig. 1C and F shows that pre-treatment with the ET_{B} receptor antagonist 100 nM BQ-788 for 5 min also had no effect on ET-1-evoked channel activity (n = 10). Figure 1E shows that ET-1 activated the same 2.6 pS channel currents in the presence of either BQ-123 or BQ-788 and in the absence of receptor antagonists. However, Fig. 1D and F illustrates that that pre-treatment with co-application of both 100 nM BQ-123 and 100 nM BQ-788 for 5 min almost completely abolished ET-1-induced channel activity (n = 8, P < 0.001).

These data showing that both ET_A and ET_B receptor antagonists must be present to block channel activity by ET-1 indicate that stimulation of both ET_A and ET_B receptors can lead to channel opening.

Stimulation of ET_A and ET_B receptors activates TRPC1 channel currents through a PKC-dependent mechanism

Previously we have shown that ET-1 and agents that deplete internal Ca²⁺ stores, cyclopiazonic acid (CPA) and BAPTA-AM, evoke native 2.6 pS TRPC1 channel currents in coronary artery myocytes which are inhibited by PKC inhibitors (Saleh *et al.* 2008; Albert *et al.* 2009). Therefore we investigated the role of PKC and TRPC1 subunits in mediating both ET_A and ET_B receptor-mediated channel activity. In these experiments we bath applied ET-1 in the presence of either BQ-788 or BQ-123 to evoke respectively ET_A or ET_B receptor-coupled pathways in cell-attached patches.

Figure 2*A* shows that the mean NP_o of ET_A receptor-mediated channel activity, activated by 100 nM ET-1 in the presence of 100 nM BQ-788, was significantly reduced from 0.37 ± 0.04 to 0.06 ± 0.01 ($83 \pm 5\%$ inhibition, n = 6, P < 0.01) by the PKC inhibitor chelerythrine (3μ M). Figure 2*B* shows that the mean




Figure 2. Stimulation of ET_{A} and ET_{B} receptors activates native TRPC1 channel currents via a PKC-dependent mechanism

A and B, stimulation of ET_A (100 nm BQ-788 present) or ET_B receptors (100 nm BQ-123 present) with 100 nm ET-1 evoked channel activity that was inhibited by co-application of 3 μ m chelerythrine in cell-attached patches held at -70 mV. C and D, stimulation of respectively ET_A and ET_B receptors evoked channel activity initially induced in cell-attached patches which was inhibited by application of 1 : 200 dilution of anti-TRPC1 antibodies following excision of patches into the inside-out configuration (i/o). E and F, following pre-incubation of anti-TRPC1 antibodies (1 : 200) with its antigenic peptide (1 : 100, AgP) bath application of the complex had no effect on ET_A receptor-mediated or ET_B receptor-mediated channel activity.

 $NP_{\rm o}$ of ET_B receptor-mediated channel activity, activated by 100 nm ET-1 in the presence of 100 nm BQ-123, was also significantly inhibited from 0.31 ± 0.08 to 0.05 ± 0.02 (84 ± 3% inhibition, n = 7, P < 0.01) by 3 μ M chelerythrine.

Figure 2C illustrates that ET_A receptor-mediated channel activity in cell-attached patches was maintained following excision into the inside-out configuration and that bath application of anti-TRPC1 antibodies to the cytosolic surface of these inside-out patches significantly reduced mean NP_o of ET_A receptor-mediated activity from 0.19 ± 0.03 to 0.01 ± 0.01 (95 ± 5% inhibition, n = 5, P < 0.01). Moreover Fig. 2D shows that anti-TRPC1 antibodies also significantly inhibited the mean NP_{0} of ET_{B} receptor-mediated channel activity from 0.22 ± 0.08 to 0.03 ± 0.02 (87 ± 8% inhibition, n = 5, P < 0.01). In control experiments, Fig. 2E and F show that following pre-incubation with their antigenic peptide, anti-TRPC1 antibodies had no effect on ET_A receptor-mediated or ET_B receptor-mediated channel activity (n = 4 for each). Channel activity often recovered, at least partially, following washout of anti-TRPC1 antibodies indicating some degree of reversibility in the conditions used.

These data show that stimulation of both ET_A and ET_B receptors activates TRPC1 channel currents through a PKC-dependent mechanism in coronary artery myocytes.

Distinct signalling pathways mediate ET_A and ET_B receptor stimulation of TRPC1 channel activity

In the next series of experiments we investigated the signalling pathways linking ET_A and ET_B receptors to PKC-mediated opening of TRPC1 channels. ET_A and ET_B G-protein-coupled receptors can be linked to different phospholipases that generate the endogenous PKC activator diacylglycerol (DAG, Ivey *et al.* 2008). Therefore we investigated the effect of biochemically characterised pharmacological inhibitors of endogenous phospholipases on ET_A and ET_B receptor-mediated TRPC1 channel activity in cell-attached patches.

Figure 3A shows that the phosphoinositolphospholipase C (PI-PLC) inhibitor U73122 $(2 \mu M)$ significantly inhibited the mean NP_{0} of ET_B receptormediated TRPC1 channel activity from 0.26 ± 0.05 to 0.04 ± 0.02 (89 ± 4% inhibition, n = 7, P < 0.01) whereas Fig. 3B demonstrates that this PI-PLC inhibitor had no effect on ET_A receptor-mediated TRPC1 channel activity (control mean \textit{NP}_{o} was 0.21 ± 0.06 and 0.18 ± 0.05 in U73122, n = 7). In addition, $2 \mu M$ U73343, an inactive analogue of U73122, had no effect on ET_{B} receptor-mediated TRPC1 channel activity (n = 4, data not shown).

The above studies indicate that a PI-PLC-mediated mechanism couples ET_B receptors to TRPC1 channel




Figure 3. Stimulation of ET_B, but not ET_A, receptors activates TRPC1 channel currents via a PLC-mediated transduction pathway in cell-attached patches

A, ET_B receptor-mediated TRPC1 channel activity was inhibited by co-application of 2 μ M U73122 at -70 mV. B, ET_A receptor-mediated TRPC1 channel activity was unaffected by co-application of 2 μ M U73122. C, mean data showing that ET_A receptor-mediated TRPC1 channel activity (ET-1-evoked NP_o in the presence of 100 nm BQ-788) at -70 mV was also unaffected by co-application of inhibitors against different phospholipases and Rho kinase (see text for details).

stimulation but is unlikely to be involved in activating native TRPC1 channels through stimulation of ET_A receptors. Therefore we investigated the effects of several established inhibitors of other phospholipases that may be involved in ET_A receptor-mediated activation of TRPC1 channel currents. Figure 3C shows that pharmacological inhibitors of phosphatidylcholine-PLC (PC-PLC, 100 μ M D-609, n = 5), cytosolic and Ca²⁺-dependent and -independent forms of phospholipase A_2 (PLA₂, 100 μ M AACOCF₃, n = 4 and 100 μ M PACOCF₃, n = 4) and phospholipase D (PLD, 100 μ M C2-ceramide, n = 6) had no effect on ET_A receptor-mediated TRPC1 channel activity. Stimulation of ET_A receptors has also been shown to activate Rho kinase (Ivey et al. 2008) but Fig. 3C shows that the Rho kinase inhibitors HA-110 (5 μ M, n=5) and Y27632 (1 μ M, n=5) had no effect on ET_A receptor-mediated TRPC1 channel activity. These data suggest that PC-PLC, PLA₂, PLD and Rho kinase are also not involved in TRPC1 channel activation initiated by ET_A receptor stimulation.

Previous studies have shown that stimulation of ET_A receptors can activate phosphoinositol-3-kinase (PI-3-kinase), which phosphorylates PIP_2 to form PIP_3 , with the latter phospholipid capable of stimulating PKC activity (see review by Ivey *et al.* 2008). Therefore we investigated the role of a PI-3-kinase-mediated mechanism on ET_A and ET_B receptor-mediated TRPC1

channel activity in cell-attached patches using selective concentrations of wortmannin and a structurally different compound, PI-828, which both inhibit PI-3-kinase. Figure 4A shows that 50 nM wortmannin significantly reduced mean NPo of ETA receptor-mediated TRPC1 channel activity from 0.23 \pm 0.06 to 0.02 \pm 0.01 (94 \pm 4% inhibition, n = 6, P < 0.01). In addition Fig. 4B shows that 3 μ M PI-828 also significantly attenuated mean NP_o of ET_A receptor-mediated TRPC1 channel activity from 0.14 ± 0.04 to 0.02 ± 0.01 (85 ± 5% inhibition, n = 5, P < 0.01). Importantly, Fig. 4C and D illustrates that 50 nM wortmannin (control mean NP_0 of 0.18 ± 0.06 and 0.18 \pm 0.07 in wortmannin, n = 6) and 3 μ M PI-828 (control mean NP_{o} of 0.31 ± 0.11 and 0.24 ± 0.08 in PI-828, n = 6) had no effect on ET_B receptor-mediated TRPC1 channel activity indicating that these reagents do not have direct non-specific effects on TRPC1 channel currents.

These results provide evidence that stimulation of ET_A and ET_B receptors evokes TRPC1 channel activity via different signal transduction mechanisms. Stimulation of ET_A receptors is coupled to TRPC1 channels via a PI-3-kinase-dependent pathway whereas a PI-PLC-dependent pathway links ET_B receptor-mediated TRPC1 channel opening, and both these pathways are likely to induce TRPC1 channel activity through a PKC-dependent mechanism.




Figure 4. Stimulation of ET_A receptors activates TRPC1 channel currents via a PI-3-kinase-mediated pathway in cell-attached patches

A and B show that ET_A receptor-mediated TRPC1 channel activity was inhibited by co-application of 50 nm wortmannin or 3 μ m PI-828, whereas C and D show that these compounds had no effect on ET_B receptor-mediated TRPC1 channel activity.

Involvement of PIP₃ in ET_A receptor-mediated activation of TRPC1 channel currents

The above results suggest that generation of PIP_3 produced from the action of PI-3-kinase on PIP_2 is required for ET_A receptor-mediated TRPC1 channel stimulation. Consequently we investigated if exogenous PIP_3 directly activates TRPC1 channel currents in coronary artery myocytes.

Figure 5A and B shows that bath application of $3 \mu M$ diC8-PIP₃, a water soluble form of PIP₃, to the cytosolic surface of inside-out patches activated cation channel activity with a mean NP_o of 0.32 ± 0.06 (n = 11) and a unitary conductance of 2.6 pS with an E_r of about 0 mV. The threshold concentration of diC8-PIP₃ was approximately $1 \mu M$ and maximum channel activation was obtained with $10-20 \mu M$ diC8-PIP₃ (data not shown). Figure 5C and D also illustrates that mean NP_o of diC8-PIP₃-evoked channel activity in inside-out patches was significantly inhibited from 0.21 ± 0.09 to 0.02 ± 0.02 ($94 \pm 4\%$ inhibition, n = 5, P < 0.01) by co-application with $3 \mu M$ chelerythrine and from 0.28 ± 0.05 to 0.03 ± 0.02 ($84 \pm 7\%$ inhibition, n = 5, P < 0.01) with anti-TRPC1 antibodies.

The role of endogenous PIP₃ in ET_A receptor-mediated stimulation of TRPC1 channel activity was investigated

using an anti-PIP₃ antibody. Figure 5*E* shows that the mean NP_{o} of ET_A receptor-mediated TRPC1 channel stimulation, initially activated in cell-attached patches in the presence of the ET_B receptor antagonist BQ-788, was significantly reduced from 0.25 ± 0.07 to 0.01 ± 0.01 (97 ± 1% inhibition, n = 6, P < 0.01) by bath application of an anti-PIP₃ antibody to the cytosolic surface of the patches. In contrast, Fig. 5*F* illustrates that an anti-PIP₃ antibody had no effect on ET_B receptor-mediated TRPC1 channel activity (control mean NP_{o} from 0.48 ± 0.08 to 0.51 ± 0.11 in anti-PIP₃ antibody, n = 6).

These data clearly show that exogenous PIP_3 and ET-1 activate the same PKC-dependent TRPC1 channel currents and also indicate that endogenous PIP_3 mediates activation of TRPC1 channel currents by ET_A receptor stimulation.

Involvement of PIP₂ in ET_B receptor-mediated activation of TRPC1 channel currents

The above results indicate that ET_B receptor-mediated TRPC1 channel activity is coupled to a PI-PLC pathway and to stimulation of PKC (see Figs 2 and 3). Previous work suggests that this biochemical cascade is likely to involve generation of DAG, through hydrolysis of PIP₂




Figure 5. PIP₃ activates TRPC1 channel currents via a PKC-dependent mechanism

A, bath application of 3 μ M diC8-PIP₃ activates cation channel activity in an inside-out patch at -70 mV. *B*, current–voltage relation of diC8-PIP₃-evoked cation channel activity yielded a unitary conductance of 2.6 pS and an *E*_r of about 0 mV. Each point was at least *n* = 4. *C* and *D*, respectively 3 μ M chelerythrine and 1 : 200 dilution of anti-TRPC1 antibodies inhibited diC8-PIP₃-induced channel activity in inside-out patches at -70 mV. *E* and *F*, co-application of 1 : 200 dilution of anti-PIP₃ antibodies reduced ET_A receptor-mediated TRPC1 channel activity (*E*) but had no effect on ET_B receptor-mediated TRPC1 channel activity (*F*).

by PI-PLC, since 1-oleoyl-2-acetyl-*sn*-glycerol (OAG), a cell-permeant DAG analogue, activates TRPC1 channel activity through a PKC-dependent mechanism in rabbit mesenteric artery, portal vein and also coronary artery (see Albert & Large, 2002; Saleh *et al.* 2006, 2008). Moreover, our recent findings extended this hypothesis by proposing an obligatory role for PIP₂ in PKC-dependent activation of TRPC1 channels in portal vein smooth muscle cells (Saleh *et al.* 2009) and therefore we investigated the effects of PIP₂ in coronary artery myocytes.

Bath application of $10 \,\mu\text{M}$ diC8-PIP₂ to inside-out patches induced cation channel activity which had a mean NP_o of 0.34 ± 0.11 at $-70 \,\text{mV}$ (n=11) and a unitary conductance of 2.6 pS and an E_r of about $0 \,\text{mV}$ (Fig. 6*Aa* and *b*). In addition, the mean NP_o of diC8-PIP₂-evoked channel activity was significantly reduced by co-application of anti-TRPC1 antibodies (from 0.24 ± 0.08 to 0.02 ± 0.01 , $88 \pm 6\%$ inhibition, n=5, P < 0.01, Fig. 6*B*) and by 3 μ M chelerythrine (from 0.31 ± 0.08 to 0.05 ± 0.03 , $97 \pm 6\%$ inhibition, n=6, P < 0.01, Fig. 6*C*). These data provide evidence that exogenous PIP₂ activates TRPC1 channel currents via a PKC-dependent mechanism.

OAG-evoked channel activity was significantly inhibited by anti-TRPC1 antibodies (Fig. 6*D*, mean NP_o from 0.23 ± 0.08 to 0.03 ± 0.01 , $87 \pm 1\%$ inhibition, n = 4, P < 0.01) and by anti-PIP₂ antibodies (Fig. 6*E*, mean NP_o from 0.32 ± 0.06 to 0.01 ± 0.01 , $97 \pm 1\%$ inhibition, n = 6, P < 0.01) in inside-out patches. Figure 6*F* also shows that when tissues were pre-treated with 20 μ M wortmannin for 30 min to deplete tissue PIP₂ levels (see Fig. 7) OAG did not evoke TRPC1 channel activity in cell-attached patches (mean NP_o of 0.01 ± 0.01 , n = 6). These results suggest that endogenous PIP₂ has an obligatory role for OAG-evoked TRPC1 channel activation.

These studies demonstrate that stimulation of ET_B receptors induces TRPC1 channel activation through stimulation of PI-PLC to generate DAG which activates PKC leading to channel opening through a mechanism involving endogenous PIP₂.




Figure 6. Obligatory role of PIP₂ in mediating OAG-induced TRPC1 channel activity via a PKC-dependent mechanism

Aa and b, bath application of 10 μ M diC8-PIP₂ activates cation channel activity in inside-out patches at -70 mV which has a unitary conductance of 2.6 pS and a E_r of about 0 mV. B and C, diC8-PIP₂-evoked channel activity is inhibited by 1 : 200 anti-TRPC1 antibodies (B) and also by 3 μ M chelerythrine (C). D and E, OAG-induced channel activity is inhibited by 1 : 200 anti-TRPC1 antibodies (D) and also by 1 : 200 anti-PIP₂ antibodies (E) in inside-out patches held at -70 mV. F, pre-treatment with 20 μ M wortmannin for 30 min prevented activation of TRPC1 activity by OAG in a cell-attached patches at -70 mV.


PIP₃ evokes TRPC1 channel activity independently of PIP₂

The present work shows that stimulation of ET_A receptors activates TRPC1 activity through a PI-3-kinase-mediated pathway involving PIP₃ (see Figs 4 and 5). Moreover we demonstrate that exogenous diC8-PIP₃ evokes PKC-dependent TRPC1 channel activity (see Fig. 5). In contrast, our data indicate that activation of TRPC1 channels by stimulation of ET_B receptors involves a permissive role for PIP₂. In a previous report we stated that PIP₂ had an obligatory role for TRPC1 channel activation in rabbit portal vein myocytes (Saleh *et al.* 2009). Therefore we investigated whether endogenous PIP₂ was necessary for activation of TRPC1 channels by PIP₃ in coronary artery smooth muscle cells.

Figure 7A shows that following pre-treatment of myocytes with 20 μ M wortmannin for 30 min to deplete PIP₂ levels (see Fig. 5*Ca*) bath application of 3 μ M

diC8-PIP₃ activated TRPC1 channel activity with a mean peak NP_0 value of 0.31 ± 0.05 (n=6) in inside-out patches, which is similar to control values of channel activity induced by $3 \mu M$ PIP₃ in the absence of wortmannin (see above and Fig. 7Aa). Figure 7B shows that anti-PIP₂ antibodies had no effect on PIP₃-induced TRPC1 channel activity in inside-out patches (control mean NP_{0} of 0.23 ± 0.06 and 0.24 ± 0.08 in the presence of anti-PIP₂ antibodies, n = 6). Both of these procedures blocked OAG-evoked TRPC1 channel activity (cf. Fig. 6E and F). In other experiments the anti-PIP₂ antibody reduced TRPC1 channel activation by both ETA and ET_B receptor stimulation (data not shown). This is predictable since PIP₂ acts as a substrate for PIP₃ generated by PI-3-kinase (ET_A pathway) and DAG produced by PI-PLC $(ET_{B} pathway).$

Therefore with regard to direct TRPC1 channel activation endogenous PIP_2 is not obligatory for TRPC1 channel activation by PIP_3 (ET_A receptor pathway) but





A, diC8-PIP₃-evoked TRPC1 channel activity in inside-out patches held at -70 mV was not inhibited by pre-treatment with 20 μ M wortmannin for 30 min. *B*, 1:200 anti-PIP₂ antibodies did not inhibit diC8-PIP₃-mediated channel activation. *Ca*, co-immunoprecipitation experiment showing association between PIP₂ and TRPC1 proteins at rest (Con) after immunoprecipitation with anti-TRPC1 antibodies and blotting with anti-PIP₂ antibodies which was reduced following pre-treatment with 20 μ M wortmannin (Wort). *Cb*, upper panel shows co-immunoprecipitation experiment following immunoprecipitation with anti-PIP₂ antibodies and blotting with anti-TRPC1 antibodies illustrating that PIP₂ association with TRPC1 proteins is unaltered following pre-treatment with 100 nm ET-1 and stimulation of ET_A (100 nm ET-1 + 100 nm BQ-788) or ET_B (100 nm ET-1 + 100 nm BQ-123) receptors. Lower panel shows a Western blot in which following preincubation with its antigenic peptide (AgP), detection of TRPC1 protein with anti-TRPC1 antibodies was reduced. *Ca* and *b* also show that wortmannin and antigenic peptide had no effect on expression of β -actin proteins. *D*, dot-blot showing the presence of PIP₂ but not PIP₃ levels in tissue lysates at rest and the reduction of PIP₂ levels and increase of PIP₃ levels following stimulation of ET_A receptors. is necessary for OAG (DAG)-induced (ET_B receptor pathway) TRPC1 channel stimulation.

To further investigate the role of PIP₂ and PIP₃ in mediating ET-1-induced TRPC1 channel activation we carried out co-immunoprecipitation and dot-blot studies. Figure 7Ca illustrates a co-immunoprecipitation experiment which shows that at rest PIP₂ is associated with TRPC1 proteins in coronary artery when tissue lysates were immunoprecipitated with anti-TRPC1 antibodies and then blotted with anti-PIP₂ antibodies to detect a predicted band of \sim 75 kDa (see Methods). In addition Fig. 7Ca shows that pre-treatment of coronary arteries with 20 μ M wortmannin for 30 min reduced PIP₂ association with TRPC1 proteins whereas total β -actin levels were not altered. The upper panel in Fig. 7Cb shows that stimulation of ET_A or ET_B receptors did not alter PIP₂ association with TRPC1 proteins following immunoprecipitation with anti-PIP₂ antibodies and blotting with anti-TRPC1 antibodies to detect a predicted band of $\sim 100 \text{ kDa}$ (see Methods). The middle panel shows a control experiment in which pre-incubation of the anti-TRPC1 antibody with its antigenic peptide (AgP) reduced the detection of the predicted band for TRPC1 proteins on a Western blot. The lower panel shows that the antigenic peptide had no effect on the expression of β -actin.

It was not possible to detect total PIP₃ levels using Western blotting or association between PIP₃ and TRPC1 proteins using co-immunoprecipitation at rest or after stimulation of ET_A and ET_B receptors. This is probably due to resting and receptor-mediated generation of PIP₃ levels being too small to resolve with the limited amounts of available coronary artery tissue. Therefore we measured PIP₃ and PIP₂ levels using tissue lysate and dot-blot techniques with their respective antibodies. Figure 7*D* illustrates that at rest total cell lysates from coronary arteries contained detectable PIP₂ but not PIP₃ whereas upon stimulation of ET_A receptors (ET-1 in the presence of BQ-788) the levels of PIP₂ were reduced and generation of PIP₃ was detected whereas levels of β -actin were unaffected.

These data provide novel evidence that PIP₃ can activate TRPC1 channels independently of PIP₂ in coronary artery myocytes.

Discussion

The present work provides the first evidence that stimulation of ET_A and ET_B receptors by ET-1 activates native TRPC1 channel currents in freshly dispersed coronary artery myocytes by two distinct parallel phosphoinositide signalling pathways. Evidence is provided to show that stimulation of ET_A receptors evokes TRPC1 channel currents through PI-3-kinase-mediated

generation of PIP₃ which leads to opening of TRPC1 channels, possibly by a direct action. In contrast ET_B receptors are coupled to PI-PLC and production of DAG leading to PIP₂-mediated TRPC1 channel activation. Moreover it appears that PKC is involved in activation of TRPC1 channel currents by both PIP₃ and PIP₂. Previously we have shown a permissive role for PIP₂ in activating TRPC1 channels in rabbit portal vein myocytes (Saleh *et al.* 2009) but this is the first demonstration that PIP₃ also activates native TRPC1 channel currents. Furthermore, to our knowledge, this is the first evidence that PI-3-kinase may be involved in activation of TRPC1 channel. Importantly, this pathway involving PI-3-kinase-mediated generation of PIP₃ represents a novel activation mechanism of TRPC channels.

ET_A receptor transduction mechanism and activation of TRPC1 channel currents

ET_A receptor-mediated stimulation of TRPC1 channel activity is blocked by PI-3-kinase inhibitors and by an anti-PIP₃ antibody which did not inhibit TRPC1 channel activation induced by ET_B receptor stimulation. Moreover exogenous PIP₃ applied to inside-out patches evoked cation channel currents with identical properties to those stimulated by ET-1, i.e. native TRPC1 channels. Importantly, PIP₃-induced TRPC1 channel activation did not require endogenous PIP₂ since PIP₃ readily activated TRPC1 channel currents in tissues pre-treated with high concentrations of wortmannin, which reduced association of PIP₂ with TRPC1. Moreover an anti-PIP₂ antibody which blocked responses to OAG did not inhibit PIP₃-evoked TRPC1 channel activity. Thus generation of PIP₃ by stimulation of ET_A receptors activates TRPC1 channels with PIP₃ possibly being the activating ligand, which represents a novel mechanism of ion channel activation.

Stimulation of ET_A receptors expressed in Chinese hamster ovary cells has been shown to increase PI-3-kinase activity and PIP₃ formation which was inhibited by low concentrations of wortmannin (Sugawara et al. 1996). Our data also show that ET_A receptor stimulation increases PIP₃ production. In vascular smooth muscle ET-1 receptor stimulation leads to activation of several signalling pathways including PI-3-kinase (see review by Boualleque et al. 2007) and this mechanism is involved in vasoconstriction (Kawanabe et al. 2004). Previously PIP₃ has been shown to bind to expressed TRPC1 proteins (Kwon *et al.* 2007) although another study suggested that PIP₃ did not activate expressed TRPC1 channels (Tseng et al. 2004). However in the same work it was shown that PIP₃ produces marked stimulation of TRPC6 channel activity (Tseng et al. 2004). Previously we indicated that the 2.6 pS ET-1-induced conductance in coronary artery

myocytes may be a heteromeric channel consisting of TRPC1, TRPC5 and TRPC6 subunits (Saleh *et al.* 2008). Therefore it is possible that the heteromeric structure of native TRPC1 channels is more sensitive to PIP₃ then heterologously expressed TRPC1 proteins or that PIP₃ binds to proposed TRPC5 or TRPC6 subunits of the native conductance in coronary artery myocytes.

The present work does not reveal how ET_A receptors are linked to PI-3-kinase in coronary arteries but in other systems it has been shown, and is generally accepted, that $G_{\beta\gamma}$ subunits activate PI-3-kinase (see Clapham & Neer, 1997; Vanhaesebroeck *et al.* 1997).

$\ensuremath{\mathsf{ET}}_{\ensuremath{\mathsf{B}}}$ receptor transduction mechanism and activation of TRPC1 channel currents

The present work shows that ET_B receptor-induced stimulation of TRPC1 channel activity was markedly inhibited by the PI-PLC inhibitor U73122, which did not effect ET_A receptor-mediated activation of TRPC1 channel activity. In addition OAG, an analogue of DAG which is a product of PI-PLC stimulation, induced TRPC1 channel activity which was also inhibited by an anti-PIP₂ antibody. Moreover OAG did not evoke TRPC1 channel activity in cells pre-treated with high concentrations of wortmannin, which depleted tissue PIP₂ levels. These electrophysiological data are consistent with a pathway in which ET_B receptors are coupled to PI-PLC, which generates DAG and subsequently induces PIP₂-mediated activation of TRPC1 channels.

Application of exogenous PIP₂ evoked TRPC1 channel currents and co-immunoprecipitation studies showed that PIP₂ co-associated with TRPC1 proteins in resting and ET-1-stimulated tissues. This finding is similar to a previous study in rabbit portal vein myocytes in which it was concluded that PIP₂ is tethered to TRPC1 proteins at rest but PKC-mediated phosphorylation of TRPC1 proteins was necessary to cause channel opening (Saleh *et al.* 2009, see Large *et al.* 2009 for more detail). We propose that a similar mechanism may be important for ET_B receptor stimulation in coronary artery myocytes.

Therefore the present work shows that both PIP_2 and PIP_3 can activate TRPC1 channels in coronary artery myocytes and our evidence is that PIP_3 is obligatory for ET_A receptor-mediated stimulation of TRPC1 channels whereas PIP_2 is necessary for ET_B receptor-mediated activation of the same ion channel.

An interesting observation is that ET_A and ET_B receptor-mediated TRPC1 channel activity is not additive and that antagonism of both ET_A and ET_B receptors is required to block ET-1-induced activation of TRPC1 channels. This suggests that both pathways were equally effective in activating TRPC1 channels with the conditions used in our experiments and may indicate a safeguard

mechanism for channel activation. Moreover these data indicate how two receptor subtypes converge onto the same TRPC1 channel utilising different transduction pathways.

Role of PKC in activation mechanism of native TRPC1 channels by ET_A and ET_B receptor stimulation

Stimulation of TRPC1 activity by both ET_A and ET_B receptors in coronary artery myocytes was almost abolished by the PKC inhibitor chelerythrine. In addition, the responses of PIP₃ and PIP₂, the proposed mediators of respectively ET_A and ET_B receptors stimulation, were also blocked by chelerythrine. Therefore it is evident that PKC plays a central role in the activation mechanism of TRPC1 channels by ET-1. Previously we demonstrated in rabbit portal vein myocytes that TRPC1 channel activation by the sarcoplasmic reticulum Ca²⁺-ATPase inhibitor cyclopiazonic acid (CPA), phorbol 12,13-dibutyrate (PDBu), a PKC stimulant, and PIP₂ was associated with phosphorylation of TRPC1 proteins which was inhibited by chelerythrine (Saleh et al. 2009). Ahmmed et al. (2004) also demonstrated that PKC-evoked phosphorylation of expressed TRPC1 channels regulated store-operated Ca²⁺ entry in cultured endothelial cells. Importantly, the present work adds significant support for the postulated activation mechanism of TRPC1 channels (see Large et al. 2009 for fully explanation) by showing that PIP₃, another notable endogenous phospholipid, also acts as a stimulatory ligand of TRPC1 channels and requires a PKC-dependent process which is likely to involve phosphorylation of TRPC1 subunits. In future experiments it will be interesting to investigate the molecular basis of PIP₃/PIP₂-mediated activation mechanisms of native TRPC1 channels using expressed heterotetrameric channels involving TRPC1 subunits.

It has been shown that PIP₃ also activates some PKC isoforms *in vitro* (Nakanishi *et al.* 1993). Therefore on ET_A receptor stimulation production of PIP₃ is likely both to activate PKC and also to activate TRPC1 channels, which leads to opening of channels through a positive feedback process in which increased PKC-dependent phosphorylation of TRPC1 proteins results in greater PIP₃-mediated channel activity. A similar transduction mechanism has been proposed to link expressed M_2 muscarinic receptors to an endogenous chloride channel in *Xenopus* oocytes (Wang *et al.* 1999).

The observation that bath application of ET-1 evoked channel activity recorded in a cell-attached patch suggests that important signalling molecule(s) outlined above translocate from receptors stimulated outside the patch to ion channels underneath the pipette tip. A characteristic of native TRPC channels is that once these signalling pathways are activated by bath applied agonists in the cell-attached configuration channel activity persists after excision into the inside-out configuration. In this configuration there is no agonist present and it is possible that processes that normally inhibit channel activity are lost (e.g. cytosolic factors) when the membrane patch is excised.

Multiple transduction mechanisms and TRPC channels in vascular smooth muscle

In cell lines, receptor-mediated activation of expressed TRPC channels is generally shown to be via stimulation of $G_{\alpha\alpha/11}$ and activation of PI-PLC (e.g. see Hardie, 2007), but in vascular smooth muscle more diverse signalling pathways are involved. Therefore α_1 -adrenoceptors and angiotensin II (Ang II) receptors are coupled to TRPC6 channels via PI-PLC in respectively rabbit portal vein and mesenteric artery myocytes (Helliwell & Large, 1997; Inoue et al. 2001; Saleh et al. 2006). In contrast constitutive TRPC3 channels in rabbit ear artery myocytes are coupled to Gai/o proteins linked PC-PLD-induced production of DAG (Albert & Large, 2004; Albert et al. 2005, 2006). The present work adds yet another signalling cascade for TRPC channels in which ET_A receptor stimulation causes PI-3-kinase-mediated production of PIP₃ to activate TRPC1 channels.

Agents that deplete intracellular Ca²⁺ stores also stimulate TRPC1 channel activity and therefore these channels are often termed store-operated channels (SOCs). The present results with ET-1 and previous work with noradrenaline in portal vein (Albert & Large, 2002) and Ang II in mesenteric artery (Saleh *et al.* 2006) indicate that membrane-delimited lipid pathways induce TRPC1 channel activity in isolated patches. Consequently TRPC1 channels behave more as receptor-operated channels than as SOCs according to their strict definition.

Phospholipids and TRPC channels

There is increasing evidence that phospholipids regulate transient receptor potential channels including TRPC channel subtypes in native vascular myocytes and in expression systems (Hardie 2007; Rohacs, 2007; Voets & Nilius, 2007; Nilius *et al.* 2008; Large *et al.* 2009). Endogenous PIP₂ inhibits the excitatory effects of DAG on TRPC6 in mesenteric artery myocytes (Albert *et al.* 2008) and also inositol 1,4,5-trisphosphate potentiates the excitatory effects of DAG on both native TRPC6 and TRPC1 channels in rabbit portal vein myocytes (Albert & Large, 2003; Liu *et al.* 2005; Saleh *et al.* 2008). PIP₂ has also been shown to have complex actions on expressed TRPC conductances with this phospholipid increasing TRPC3, TRPC6 and TRPC7 channel activity (Lemonnier *et al.* 2007), inhibiting TRPC4 whole-cell currents (Otsuguro

et al. 2008) and having both excitatory and inhibitory effects on TRPC5 channel activity (Trebak *et al.* 2008). There is little information on the action on PIP₃ on TRPC channels although this phospholipid has been shown to increase expressed TRPC6-mediated Ca²⁺ entry in HEK293 cells recorded with a Ca²⁺-sensitive dye (Tseng *et al.* 2004). However the present data provide the first direct evidence that PIP₃ activates native TRPC channels in any cell type.

Conclusion

This study demonstrates that ET-1 activates native TRPC1 channels in rabbit coronary artery myocytes using two distinct phospholipid signalling pathways. The data show that PIP₃ and PIP₂ mediate the responses to respectively ET_A and ET_B receptor stimulation and facilitate opening of native TRPC1 channels. This is the first demonstration that PIP₃ activates native TRPC1 channels in vascular smooth muscle.

References

- Ahmmed GU, Mehta D, Vogel S, Holinstat M, Paria BC, Tiruppathu C & Malik AB (2004). Protein kinase C α phosphorylates the TRPC1 channel and regulates storeoperated Ca²⁺ entry in endothelial cells. *J Biol Chem* **279**, 20941–20949.
- Albert AP & Large WA (2002). Activation of store-operated channels by noradrenaline via protein kinase C in rabbit portal vein myocytes. *J Physiol* **544**, 113–125.
- Albert AP & Large WA (2003). Synergism between inositol phosphates and diacylglycerol on native TRPC6-like channels in rabbit portal vein myocytes. *J Physiol* **552**, 789–795.
- Albert AP & Large WA (2004). Inhibitory regulation of constitutive transient receptor potential-like cation channels in rabbit ear artery myocytes. *J Physiol* **560**, 169–180.
- Albert AP, Piper AS & Large WA (2005). Role of phospholipase D and diacylglycerol in activating constitutive TRPC-like cation channels in rabbit ear artery myocytes. *J Physiol* **566**, 769–780.
- Albert AP, Pucovsky V, Prestwich SA & Large WA (2006). TRPC3 properties of a native constitutively active Ca²⁺-permeable cation channel in rabbit ear artery myocytes. *J Physiol* **571**, 361–369.
- Albert AP, Saleh SN & Large WA (2008). Inhibition of native TRPC6 channel activity by phosphatidylinositol-4,5-bisphosphate in mesenteric artery myocytes. *J Physiol* **586**, 3087–3095.
- Albert AP, Saleh SN & Large WA (2009). Identification of canonical transient receptor potential (TRPC) channel proteins in native vascular smooth muscle cells. *Curr Med Chem* **16**, 1158–1165.

Boualleque A, Daou GB & Srivastava AK (2007). Endothelin-1induced signalling pathways in vascular smooth muscle cells. *Curr Vasc Pharmacol* **5**, 45–52.

Clapham DE & Neer EJ (1997). G proteins βγ subunits. *Annu Rev Pharmacol Toxicol* **37**, 167–203.

Davenport AP (2002). International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. *Pharmacol Rev* 54, 219–226.

Davenport AP & Battistini B (2002). Classification of endothelin receptors and antagonists in clinical development. *Clinical Sci* **103**, 15–35.

Drummond GB (2009). Reporting ethical matters in *The Journal of Physiology*: standards and advice. *J Physiol* **587**, 713–719.

Fukami K, Matsuoka K, Nakanishi O, Yamakawa A, Kawai S & Takenawa T (1988). Antibody to phospyhatidylinositol 4,5-bisphosphate inhibits oncogene-induced mitogenesis. *Proc Natl Acad Sci U S A* 85, 9057–9061.

Hamill OP, Marty A, Neher E, Sakmann B & Sigworth FJ (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. *Pflugers Arch* **391**, 85–100.

Hardie RC (2007). TRP channels and lipids: from *Drosophila* to mammalian physiology. *J Physiol* **578**, 9–24.

Helliwell RM & Large WA (1997). α_1 -Adrenoceptor activation of a non-selective cation current in rabbit portal vein by 1,2-diacyl-*sn*-glycerol. *J Physiol* **499**, 417–428.

Inoue R, Okada T, Onoue H, Harea Y, Shimizu S, Naitoh S, Ito Y & Mori Y (2001). The transient receptor potential protein homologue TRP6 is the essential component of vascular α -adrenoceptor-activated Ca²⁺-permeable cation channel. *Circ Res* **88**, 325–337.

Ivey ME, Osman N & Little PJ (2008). Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. *Atherosclerosis* 199, 237–147.

Kawanabe Y, Hashimoto N & Masaki T (2004). Effects of phosphoinositide 3-kinase on endothelin-1-induced activation of voltage-independent Ca²⁺ channels and vasoconstriction. *Biochem Pharmacol* **68**, 215–221.

Kinlay S, Behrendt D, Wainstein M, Beltrame, Fang JC, Creager MA, Selwyn AP & Ganz P (2001). Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. *Circulation* **104**, 1114–1118.

Kwon Y, Hofmann T & Montell C (2007). Integration of phosphoinositide- and calmodulin-mediated regulation of TRPC6. *Mol Cell* **25**, 491–503.

Large WA, Saleh SN & Albert AP (2009). Role of phosphoinositol 4,5-bisphosphate and diacylglycerol in regulating native TRPC channel proteins in vascular smooth muscle. *Cell Calcium* **45**, 574–582.

Lemonnier L, Trebak M & Putney JW Jr (2007). Complex regulation of the TRPC3, 6 and 7 channel subfamily by diacylglycerol and phosphatidylinositol-4,5-bisphosphate. *Cell Calcium* **43**, 506–514.

Liu M, Albert AP & Large WA (2005). Facilitatory effect of Ins(1,4,5)P₃ on store-operated Ca²⁺-permeable cation channels in rabbit portal vein myocytes. *J Physiol* **566**, 161–171.

Miwa S, Kawanabe Y, Okamoto Y & Masaki T (2005). Ca²⁺ entry involved in endothelin-1-induced contractions of vascular smooth muscle cells. *J Smooth Muscle Res* **41**, 61–75.

Nakanishi H, Brewer KA & Exton JH (1993). Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem* **268**, 13–16.

Nilius B, Owsianik G & Voets T (2008). Transient receptor potential channels meet phosphoinositides. *EMBO J* 27, 2809–2816.

Otsuguro K, Tang J, Tang Y, Xiao R, Freichel M, Tsvilovskyy, Ito S, Flockerzi V, Zhu M & Zholos AV (2008). Isoform-specific inhibition of TRPC4 channel by phosphatidylinositol 4,5-bisphosphate. *J Biol Chem* **283**, 10026–10036.

Peppiatt-Wildman CM, Albert AP, Saleh SN & Large WA (2007). Endothelin-1 activates a Ca²⁺-permeable cation channel with TRPC3 and TRPC7 properties in rabbit coronary artery myocytes. *J Physiol* **580**, 755–764.

Rohacs T (2007). Regulation of TRP channels by PIP₂. *Pflugers Arch* **453**, 753–762.

Saleh SN, Albert AP, Peppiatt CM & Large WA (2006). Angiotensin II activates two cation conductances with distinct TRPC1 and TRPC6 channel properties in rabbit mesenteric artery myocytes. *J Physiol* **577**, 479–495.

Saleh SN, Albert AP, Peppiatt-Wildman CM & Large WA (2008). Diverse properties of store-operated TRPC channels activated by protein kinase C in vascular myocytes. *J Physiol* **586**, 2463–2476.

Saleh SN, Albert AP & Large WA (2009). Obligatory role for phosphatidylinositol 4,5-bisphosphate in activation of native TRPC1 store-operated channels in vascular myocytes. *J Physiol* **587**, 531–540.

Schiffrin EL & Touyz RM (1998). Vascular biology of endothelin. *J Cardiovasc Pharmacol* **32**, S2–S13.

Sumner MJ, Cannon TR, Mundin JW, White DG & Watts IS. (1992). Endothelin ET_A and ET_B receptors mediate vascular smooth muscle contraction. *Br J Pharmacol* **107**, 858–860.

Sugawara F, Ninomiya H, Okamoto Y, Miwa S, Mazda O, Katsura Y & Masaki T (1996). Endothelin-1-induced mitogenic responses of Chinese hamster ovary cells expressing human endothelinA: the role of a wortmannin-sensitive signalling pathway. *Mol Pharmacol* **49**, 447–457.

Tseng PH, Lin HP, Hu H, Wang C, Zhu MX & Chen CS (2004). The canonical transient receptor potential 6 channel as a putative phosphatidylinositol-3,4,5- trisphosphate-sensitive calcium entry system. *Biochemistry* **43**, 11701–11708.

Trebak M, Lemonnier L, Dehaven WI, Wedel BJ, Bird GS & Putney JW Jr (2008). Complex functions of phosphatidylinositol-4,5-bisphosphate on regulation of TRPC5 cation channels. *Pflugers Arch* **457**, 757–769.

Vanhaesebroeck B, Leevers SJ, Panayotou G & Waterfield MD (1997). Phosphoinositide-3-kinases: a conserved family of signal transducers. *Trends Biochem Sci* **22**, 267–272.

Voets T & Nilius B (2007). Modulation of TRPs by PIPs. *J Physiol* **582**, 939–944.

Wang YX, Dhulipala PD, Li L, Benovic JL & Kotlikoff MI (1999). Coupling of M_2 muscarinic receptors to membrane ion channels via phosphoinositide-3-kinase γ and atypical protein kinase C. *J Biol Chem* **274**, 13859–13864.

Author contributions

S.N.S. carried out the experimental work and figure preparation. A.P.A. and W.A.L. were involved in the conception and design of the study, interpretation of data, and drafting of the manuscript. All authors were involved in revising the manuscript and approved the final version.

Acknowledgements

This work was supported by The Wellcome Trust.